How have the shares performed?
Cellect Biotechnology Ltd. (APOP) saw an uptrend of 7.57% in the recent trading with $3.27 being its most recent. The current price level -54.27% lower than the highest price of $7.15 marked by the stock while trading over the past 52-weeks, whereas it is 98.24% higher than the lowest price of $1.65 the company dropped to over past 52-weeks. The latest news story on APOP appeared in GlobeNewswire under the title “Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals” on Jun-16-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -7.37% below one month high and is +29.25% above of the lowest during that time. Looking into the simple moving average, Cellect Biotechnology Ltd. (APOP)’s stock stands at a SMA-50 of $2.78 while that of 5-day is reading $3.13.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and APOP’s SMA-200 as of now is $2.65.
Cellect Biotechnology Ltd. Earnings – What Happened With APOP
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Cellect Biotechnology Ltd. (APOP) last released financial results for the quarter that ended 9/29/2018, posting a surprise factor of -417.90% for net revenue.
APOP – Cellect Biotechnology Ltd. Stock Earnings Estimates
The perspective of Cellect Biotechnology Ltd. (NASDAQ:APOP)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.28 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -1.45.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 3.91 million. APOP does have institutional investors; and they hold 14.91% of the stock.
Cellect Biotechnology Ltd. – Insider Activity and Holdings
As on Mar 30, 2021, Renaissance Technologies, LLC was the top most holder in Cellect Biotechnology Ltd. (NASDAQ:APOP) with an ownership of 0.13 million shares of the company or 3.94% of the stake worth $0.42 million. The filing also reveals HRT Financial LLC as the second largest holder in the company with a control over 0.61% of the outstanding shares. Its stake is worth $65208.0 for having 20767.0 shares in hand.
Virtu Financial LLC also came holding a key position in the company during the recent quarter and it now holds 0.60% of the outstanding shares. With this there are now 14 institutions which have possession in APOP’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. The count was 2.61 for long-term debt to equity ratio.
Technical Analysis of Cellect Biotechnology Ltd. (NASDAQ:APOP) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Cellect Biotechnology Ltd. (APOP), we notice that the stock’s 20-day average volume is at 439,510 shares and 50% of short term indicators are suggesting the stock as Buy. Its 50-day average volume of 418,866 shares. And to end, APOP’s 100-day average volume is 1,433,223 shares with 100% of the long-term indicators pointing towards Buy for the stock.